Clinical Trials | April 16, 2024
Suven Life Sciences to present phase-2 results on Samelisant at AAN 2024
Global Phase-3 study initiation expected in the second half of 2024
Global Phase-3 study initiation expected in the second half of 2024
Suven Life Sciences has reported total income of Rs. 9.43 crores during the period ended June 30, 2023
Suven Life Sciences completed enrollment of patients to the phase-2, PoC clinical study of samelisant (SUVN-G3031) for the treatment of narcolepsy with or without cataplexy in USA and Canada
The company has reported total income of Rs. 4.59 crores during the period ended September 30, 2022
Suven Life Sciences has reported total income of Rs. 3.97 crores during the period ended June 30, 2022
This multi-centre study (sites in the US and Europe) comprising about 387 patients is likely to be completed in about 36 months and the topline result is expected by the end of 2024
Suven has already begun planning a global Phase 3 registrational program for MDD based on the results
Independent DSMB recommends continuation of Masupirdine without modifications as enrollment reaches 88% in global trial
Anthem’s business comprises of CRDMO services and the manufacture and sale of Specialty Ingredients
Advent will also be making an open offer to acquire additional 26% of the outstanding equity shares of the company from the public shareholders.
Subscribe To Our Newsletter & Stay Updated
_256_275.jpeg)
